伊维菌素对轻中度COVID-19合并合并症成人疾病进展的疗效:I-TECH随机临床试验
I-TECH为开放标签随机临床试验,2021年5月31日至10月25日在马来西亚20家公立医院和1家COVID-19检疫中心开展,纳入症状出现1周内、年龄≥50岁、实验室确诊COVID-19、有合并症且轻中度的患者490例。患者1:1随机接受口服伊维菌素0.4 mg/kg每日5天联合标准治疗(n=241)或单纯标准治疗(n=249)。主要终点进展为重症(需补氧维持SpO2≥95%的低氧阶段)在伊维菌素组21.6%(52/241)vs 对照组17.3%(43/249),RR 1.25(95%CI 0.87-1.80;P=.25),无显著差异;机械通气、ICU入住、28天院内死亡等次要终点均无显著差异。结论为早期伊维菌素治疗未预防重症进展,研究结果不支持对COVID-19患者使用伊维菌素。
要点
- 伊维菌素组52/241(21.6%)vs 对照组43/249(17.3%)进展为重症(需补氧维持SpO2≥95%),RR 1.25(95%CI 0.87-1.80;P=.25),无显著差异。
- 机械通气4/241(1.7%)vs 10/249(4.0%),RR 0.41(95%CI 0.13-1.30;P=.17);ICU入住6/241(2.4%)vs 8/249(3.2%),RR 0.78(95%CI 0.27-2.20;P=.79)。
- 28天院内死亡3/241(1.2%)vs 10/249(4.0%),RR 0.31(95%CI 0.09-1.11;P=.09),无显著差异。
- 最常见不良事件为腹泻:伊维菌素组14例(5.8%)vs 对照组4例(1.6%)。
- 研究结论:早期伊维菌素治疗未预防重症进展,不支持对COVID-19患者使用伊维菌素。
适用人群与场景
- 年龄≥50岁、实验室确诊COVID-19、有合并症、轻中度疾病、症状出现1周内的患者。
- 场景:马来西亚20家公立医院和1家COVID-19检疫中心。
诊断标准与关键阈值
- 重症(主要终点)定义:需补充氧气以维持脉搏血氧饱和度≥95%的低氧阶段。
处置流程与药物剂量
- 伊维菌素组:口服伊维菌素0.4 mg/kg体重,每日1次,共5天,联合标准治疗。
- 标准治疗:对症治疗,并根据临床表现、实验室检查和胸部影像学监测早期恶化征象。
研究设计与关键结果
- 开放标签随机临床试验(I-TECH),在马来西亚20家公立医院和1家COVID-19检疫中心开展,2021年5月31日至10月25日纳入490例(平均[SD]年龄62.5[8.7]岁;女性267例[54.5%])。
- 主要终点:伊维菌素组52/241(21.6%)vs 对照组43/249(17.3%)进展为重症,RR 1.25(95%CI 0.87-1.80;P=.25)。
- 机械通气:伊维菌素组4/241(1.7%)vs 对照组10/249(4.0%),RR 0.41(95%CI 0.13-1.30;P=.17)。
- ICU入住:伊维菌素组6/241(2.4%)vs 对照组8/249(3.2%),RR 0.78(95%CI 0.27-2.20;P=.79)。
- 28天院内死亡:伊维菌素组3/241(1.2%)vs 对照组10/249(4.0%),RR 0.31(95%CI 0.09-1.11;P=.09)。
- 最常见不良事件为腹泻:伊维菌素组14例(5.8%)vs 对照组4例(1.6%)。
证据类型、等级与局限
- 证据类型:开放标签随机临床试验(I-TECH)。
- 结论:早期伊维菌素治疗未预防重症进展,研究结果不支持对COVID-19患者使用伊维菌素。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论:研究结果不支持对COVID-19患者使用伊维菌素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed.
OBJECTIVE: To determine the efficacy of ivermectin in preventing progression to severe disease among high-risk patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: The Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients (I-TECH) study was an open-label randomized clinical trial conducted at 20 public hospitals and a COVID-19 quarantine center in Malaysia between May 31 and October 25, 2021. Within the first week of patients' symptom onset, the study enrolled patients 50 years and older with laboratory-confirmed COVID-19, comorbidities, and mild to moderate disease.
INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive either oral ivermectin, 0.4 mg/kg body weight daily for 5 days, plus standard of care (n = 241) or standard of care alone (n = 249). The standard of care consisted of symptomatic therapy and monitoring for signs of early deterioration based on clinical findings, laboratory test results, and chest imaging.
MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients who progressed to severe disease, defined as the hypoxic stage requiring supplemental oxygen to maintain pulse oximetry oxygen saturation of 95% or higher. Secondary outcomes of the trial included the rates of mechanical ventilation, intensive care unit admission, 28-day in-hospital mortality, and adverse events.
RESULTS: Among 490 patients included in the primary analysis (mean [SD] age, 62.5 [8.7] years; 267 women [54.5%]), 52 of 241 patients (21.6%) in the ivermectin group and 43 of 249 patients (17.3%) in the control group progressed to severe disease (relative risk [RR], 1.25; 95% CI, 0.87-1.80; P = .25). For all prespecified secondary outcomes, there were no significant differences between groups. Mechanical ventilation occurred in 4 (1.7%) vs 10 (4.0%) (RR, 0.41; 95% CI, 0.13-1.30; P = .17), intensive care unit admission in 6 (2.4%) vs 8 (3.2%) (RR, 0.78; 95% CI, 0.27-2.20; P = .79), and 28-day in-hospital death in 3 (1.2%) vs 10 (4.0%) (RR, 0.31; 95% CI, 0.09-1.11; P = .09). The most common adverse event reported was diarrhea (14 [5.8%] in the ivermectin group and 4 [1.6%] in the control group).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04920942.
参考来源
- Lim SCL, Hor CP, Tay KH, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med. 2022. PMID: 35179551. doi:10.1001/jamainternmed.2022.0189
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。